Immunotherapy targeting CTLA‐4 and PD1/PD‐L1 immune checkpoints enhances T cell‐mediated immune reactions against cancer, which appears to be effective for tumors with more mutation burden and mutation‐associated neoantigens (Anagnostou et al., 2017; Rizvi et al., 2015). The gene discussed is CD274; the disease is cancer.